6:28 PM
 | 
Oct 18, 2012
 |  BC Extra  |  Company News

FDA delays decision on Biogen Idec's BG-12

FDA extended the PDUFA date by three months for an NDA from Biogen Idec Inc. (NASDAQ:BIIB) for BG-12 to treat multiple sclerosis (MS). The delay would move a potential decision into early next year; Biogen Idec had...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >